KR102621513B1 - 9h-피롤로-디피리딘 유도체 - Google Patents
9h-피롤로-디피리딘 유도체 Download PDFInfo
- Publication number
- KR102621513B1 KR102621513B1 KR1020177024371A KR20177024371A KR102621513B1 KR 102621513 B1 KR102621513 B1 KR 102621513B1 KR 1020177024371 A KR1020177024371 A KR 1020177024371A KR 20177024371 A KR20177024371 A KR 20177024371A KR 102621513 B1 KR102621513 B1 KR 102621513B1
- Authority
- KR
- South Korea
- Prior art keywords
- pyrrolo
- dipyridine
- methyl
- dipyridin
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15153448 | 2015-02-02 | ||
| EP15153448.4 | 2015-02-02 | ||
| PCT/EP2016/051993 WO2016124508A1 (en) | 2015-02-02 | 2016-01-29 | 9h-pyrrolo-dipyridine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170113607A KR20170113607A (ko) | 2017-10-12 |
| KR102621513B1 true KR102621513B1 (ko) | 2024-01-04 |
Family
ID=52477553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177024371A Active KR102621513B1 (ko) | 2015-02-02 | 2016-01-29 | 9h-피롤로-디피리딘 유도체 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180022748A1 (enExample) |
| EP (1) | EP3253762B1 (enExample) |
| JP (1) | JP6579670B2 (enExample) |
| KR (1) | KR102621513B1 (enExample) |
| CN (1) | CN107207508B (enExample) |
| AU (1) | AU2016214537B2 (enExample) |
| BR (1) | BR112017016311A2 (enExample) |
| CA (1) | CA2973648C (enExample) |
| CL (1) | CL2017001923A1 (enExample) |
| DK (1) | DK3253762T3 (enExample) |
| EA (1) | EA036518B1 (enExample) |
| ES (1) | ES2875734T3 (enExample) |
| IL (1) | IL253381B (enExample) |
| MX (1) | MX378155B (enExample) |
| MY (1) | MY191590A (enExample) |
| SG (1) | SG11201705727TA (enExample) |
| WO (1) | WO2016124508A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2247558T5 (pl) | 2008-02-14 | 2024-10-14 | Eli Lilly And Company | Nowe środki obrazujące do wykrywania czynnościowych zaburzeń neurologicznych |
| SG11201705727TA (en) * | 2015-02-02 | 2017-08-30 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
| CN115650982A (zh) * | 2016-07-22 | 2023-01-31 | Ac免疫有限公司 | 用于成像tau蛋白聚集体的化合物 |
| EP3487545A1 (en) | 2016-07-22 | 2019-05-29 | AC Immune S.A. | Compounds for imaging tau protein aggregates |
| ES2847903T3 (es) * | 2016-09-09 | 2021-08-04 | Hoffmann La Roche | Procedimiento para la preparación de 2-(6-nitropiridin-3-il)-9H-dipirido[2,3-b;3',4'-d]pirrol |
| KR20230127371A (ko) * | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| US11660287B2 (en) | 2017-06-02 | 2023-05-30 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating spinocerebellar ataxia |
| MX393052B (es) | 2017-06-02 | 2025-03-24 | Fujifilm Toyama Chemical Co Ltd | Agente para prevenir o tratar atrofia cerebral. |
| WO2018221731A1 (ja) * | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | タウオパチー予防または治療剤 |
| EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA |
| BR112019024983A2 (pt) | 2017-06-02 | 2020-06-23 | Fujifilm Toyama Chemical Co., Ltd. | Agente para reduzir a quantidade de proteína b amiloide |
| EP3705121B1 (en) | 2017-10-30 | 2023-08-30 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
| CN111868062B (zh) * | 2018-01-24 | 2023-07-07 | Ac免疫有限公司 | 制备显像化合物的方法 |
| EP3743426A1 (en) * | 2018-01-24 | 2020-12-02 | AC Immune SA | Azacarboline compounds for the detection of tau aggregates |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
| US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013176698A1 (en) | 2012-05-22 | 2013-11-28 | Eli Lilly And Company | Carboline and carbazole based imaging agents for detecting neurological dysfunction |
| WO2014194169A1 (en) | 2013-05-31 | 2014-12-04 | The General Hospital Corporation | Radiosynthesis of tau radiopharmaceuticals |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1268771A (en) | 1968-03-15 | 1972-03-29 | Glaxo Lab Ltd | Azacarbazoles |
| WO2008132454A1 (en) * | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| PL2247558T5 (pl) * | 2008-02-14 | 2024-10-14 | Eli Lilly And Company | Nowe środki obrazujące do wykrywania czynnościowych zaburzeń neurologicznych |
| JP5557849B2 (ja) * | 2008-12-19 | 2014-07-23 | ブリストル−マイヤーズ スクイブ カンパニー | カルバゾールおよびカルボリンキナーゼ阻害剤 |
| US9774356B2 (en) * | 2013-07-24 | 2017-09-26 | Telefonaktiebolaget Lm Ericsson (Publ) | Method and apparatus relating to reception of radio signals |
| DK3055308T3 (en) * | 2013-10-08 | 2018-01-22 | Hoffmann La Roche | Diazacarbazole derivatives as tau PET ligands |
| WO2015110263A1 (en) * | 2014-01-21 | 2015-07-30 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins |
| SG11201705727TA (en) * | 2015-02-02 | 2017-08-30 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
-
2016
- 2016-01-29 SG SG11201705727TA patent/SG11201705727TA/en unknown
- 2016-01-29 BR BR112017016311A patent/BR112017016311A2/pt not_active Application Discontinuation
- 2016-01-29 DK DK16702121.1T patent/DK3253762T3/da active
- 2016-01-29 KR KR1020177024371A patent/KR102621513B1/ko active Active
- 2016-01-29 US US15/547,980 patent/US20180022748A1/en not_active Abandoned
- 2016-01-29 EA EA201791733A patent/EA036518B1/ru not_active IP Right Cessation
- 2016-01-29 MY MYPI2017702668A patent/MY191590A/en unknown
- 2016-01-29 MX MX2017009505A patent/MX378155B/es unknown
- 2016-01-29 AU AU2016214537A patent/AU2016214537B2/en active Active
- 2016-01-29 EP EP16702121.1A patent/EP3253762B1/en active Active
- 2016-01-29 JP JP2017540724A patent/JP6579670B2/ja active Active
- 2016-01-29 ES ES16702121T patent/ES2875734T3/es active Active
- 2016-01-29 CN CN201680008314.3A patent/CN107207508B/zh active Active
- 2016-01-29 CA CA2973648A patent/CA2973648C/en active Active
- 2016-01-29 WO PCT/EP2016/051993 patent/WO2016124508A1/en not_active Ceased
-
2017
- 2017-07-10 IL IL253381A patent/IL253381B/en active IP Right Grant
- 2017-07-27 CL CL2017001923A patent/CL2017001923A1/es unknown
-
2020
- 2020-01-22 US US16/749,537 patent/US11312716B2/en active Active
-
2022
- 2022-03-21 US US17/700,075 patent/US12006316B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013176698A1 (en) | 2012-05-22 | 2013-11-28 | Eli Lilly And Company | Carboline and carbazole based imaging agents for detecting neurological dysfunction |
| WO2014194169A1 (en) | 2013-05-31 | 2014-12-04 | The General Hospital Corporation | Radiosynthesis of tau radiopharmaceuticals |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107207508A (zh) | 2017-09-26 |
| CL2017001923A1 (es) | 2018-02-16 |
| CA2973648C (en) | 2023-09-26 |
| EA201791733A1 (ru) | 2018-01-31 |
| US20220213103A1 (en) | 2022-07-07 |
| JP6579670B2 (ja) | 2019-09-25 |
| MX2017009505A (es) | 2017-11-02 |
| US12006316B2 (en) | 2024-06-11 |
| BR112017016311A2 (pt) | 2018-03-27 |
| CA2973648A1 (en) | 2016-08-11 |
| MX378155B (es) | 2025-03-10 |
| ES2875734T3 (es) | 2021-11-11 |
| CN107207508B (zh) | 2020-02-28 |
| EP3253762B1 (en) | 2021-05-05 |
| EP3253762A1 (en) | 2017-12-13 |
| JP2018503673A (ja) | 2018-02-08 |
| MY191590A (en) | 2022-06-30 |
| AU2016214537A1 (en) | 2017-08-03 |
| SG11201705727TA (en) | 2017-08-30 |
| US11312716B2 (en) | 2022-04-26 |
| IL253381A0 (en) | 2017-09-28 |
| EA036518B1 (ru) | 2020-11-18 |
| US20180022748A1 (en) | 2018-01-25 |
| WO2016124508A1 (en) | 2016-08-11 |
| DK3253762T3 (da) | 2021-07-19 |
| IL253381B (en) | 2020-10-29 |
| KR20170113607A (ko) | 2017-10-12 |
| AU2016214537B2 (en) | 2018-05-10 |
| US20210047326A1 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12006316B2 (en) | 9H-pyrrolo-dipyridine derivatives | |
| JP6513107B2 (ja) | 神経原線維濃縮体のイメージング剤としてのピロロ［２，３−ｃ］ピリジン | |
| KR102516711B1 (ko) | P2x7 조절제 | |
| AU2015276699B2 (en) | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor | |
| CA2904618A1 (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| EP2569306A1 (en) | Heteroaryloxycarbocyclyl compounds as pde10 inhibitors | |
| ES2967489T3 (es) | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 | |
| WO2019074809A1 (en) | INDAZOLYL-SPIRO [2.2] PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| TW201333005A (zh) | １,５－萘啶衍生物與含此之ｍｅｌｋ抑制劑 | |
| CN119698416A (zh) | 作为ripk2抑制剂的咪唑并(1,2-a)吡啶衍生物 | |
| WO2016120808A1 (en) | Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof | |
| CN114133394B (zh) | 一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途 | |
| JP7604067B2 (ja) | ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途 | |
| JP2024544245A (ja) | Ｔｙｋ２阻害剤の固体形態、調製方法、及びその使用 | |
| EP3527209A1 (en) | Pharmaceutical 6,5 heterobicyclic ring derivatives | |
| TW202502336A (zh) | 治療發炎性疾病之方法 | |
| CN121127273A (zh) | α-突触核蛋白结合剂及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170830 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210113 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230127 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20231124 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240102 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240102 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |